{"id":465,"date":"2026-08-28T06:56:05","date_gmt":"2026-08-28T06:56:05","guid":{"rendered":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/pt-br\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","title":{"rendered":"SS-31, Elamipretide e Forzinity: Por que a distin\u00e7\u00e3o entre medicamentos acabados \u00e9 importante"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">SS-31 e elamipretide s\u00e3o nomes usados \u200b\u200b\u200b\u200bem torno do mesmo pept\u00eddeo direcionado \u00e0s mitoc\u00f4ndrias, mas Forzinity \u00e9 um medicamento acabado espec\u00edfico aprovado pelo FDA com aplica\u00e7\u00e3o, formula\u00e7\u00e3o, controles de fabrica\u00e7\u00e3o e r\u00f3tulo aprovados. Um nome de ingrediente correspondente n\u00e3o cria equival\u00eancia farmac\u00eautica.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">O que o registro mostra<\/h2><ul class=\"wp-block-list\"><li>A indica\u00e7\u00e3o aprovada est\u00e1 limitada a pacientes com s\u00edndrome de Barth com peso m\u00ednimo de 30 kg.<\/li><li>A aprova\u00e7\u00e3o acelerada n\u00e3o elimina a exig\u00eancia de provas confirmat\u00f3rias.<\/li><li>Um lote do cat\u00e1logo SS-31 deve ser descrito por seu pr\u00f3prio registro anal\u00edtico, e n\u00e3o por empr\u00e9stimo do status do produto aprovado.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1536\" height=\"1024\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828.png\" alt=\"Cientista revisando imagens da membrana mitocondrial e dados de metabolismo energ\u00e9tico\" class=\"wp-image-458\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828.png 1536w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828-300x200.png 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828-1024x683.png 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828-768x512.png 768w\" sizes=\"auto, (max-width: 1536px) 100vw, 1536px\" \/><figcaption class=\"wp-element-caption\">Ilustra\u00e7\u00e3o editorial original utilizada para identificar o tema da pesquisa. N\u00e3o representa lote de cat\u00e1logo, medicamento aprovado, resultado de ensaio ou uso cl\u00ednico.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">O limite de identidade e evid\u00eancia<\/h2><p class=\"wp-block-paragraph\">A aplica\u00e7\u00e3o FDA inclui informa\u00e7\u00f5es espec\u00edficas de qu\u00edmica, fabrica\u00e7\u00e3o, seguran\u00e7a e rotulagem do produto. Nada disso \u00e9 transferido automaticamente para um material separado com o nome elamipretide ou SS-31.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Produto acabado aprovado<\/strong><span>Forzinidade (elamipretida)<\/span><\/div><div class=\"pim-evidence-row\"><strong>Limite de indica\u00e7\u00e3o<\/strong><span>S\u00edndrome de Barth; peso corporal pelo menos 30 kg<\/span><\/div><div class=\"pim-evidence-row\"><strong>Registro de material de pesquisa<\/strong><span>Sequ\u00eancia, forma, ensaio, impurezas e rastreabilidade do lote<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">O que pertence ao registro material<\/h2><p class=\"wp-block-paragraph\">A c\u00f3pia da pesquisa deve indicar qual \u00e9 o lote do cat\u00e1logo e como foi testado. N\u00e3o deve dizer \u201cSS-31 aprovado por FDA\u201d, a menos que esteja discutindo o produto acabado aprovado em seu contexto regulat\u00f3rio exato.<\/p><h2 class=\"wp-block-heading\">Regra editorial<\/h2><p class=\"wp-block-paragraph\">Use o nome exato da interven\u00e7\u00e3o, modelo, popula\u00e7\u00e3o e desfecho do registro citado. N\u00e3o converta uma associa\u00e7\u00e3o, mecanismo, resultado animal, registro de medicamento acabado aprovado ou teste anal\u00edtico em uma afirma\u00e7\u00e3o sobre um lote de cat\u00e1logo n\u00e3o relacionado.<\/p>","protected":false},"excerpt":{"rendered":"<p>SS-31 e elamipretide s\u00e3o nomes usados \u200b\u200b\u200b\u200bem torno do mesmo pept\u00eddeo direcionado \u00e0s mitoc\u00f4ndrias, mas Forzinity \u00e9 um medicamento acabado espec\u00edfico aprovado pelo FDA com aplica\u00e7\u00e3o, formula\u00e7\u00e3o, controles de fabrica\u00e7\u00e3o e r\u00f3tulo aprovados. Um nome de ingrediente correspondente n\u00e3o cria equival\u00eancia farmac\u00eautica.<\/p>","protected":false},"author":1,"featured_media":630,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"364","pim_article_type":"Evidence and material-quality guide","pim_evidence_level":"FDA label\/approval distinction and research-material quality review","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"FDA Drug Trials Snapshot: Forzinity\",\"url\":\"https:\/\/www.fda.gov\/drugs\/drug-trials-snapshots\/drug-trials-snapshots-forzinity\",\"note\":\"Trial population, endpoint results and approval basis.\"},{\"title\":\"Elamipretide phase 2\/3 Barth syndrome crossover trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33077895\/\",\"note\":\"Primary published trial; PMID 33077895.\"},{\"title\":\"FDA accelerated approval announcement for Forzinity\",\"url\":\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-treatment-barth-syndrome\",\"note\":\"Approval scope and confirmatory requirement.\"}]","footnotes":""},"categories":[20],"tags":[],"class_list":["post-465","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-quality-guides"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters - NHD<\/title>\n<meta name=\"description\" content=\"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/pt-br\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters\" \/>\n<meta property=\"og:description\" content=\"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/pt-br\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\"},\"wordCount\":246,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\",\"articleSection\":[\"Evidence &amp; Quality Guides\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\",\"name\":\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/pt-br\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SS-31, Elamipretide e Forzinity: Por que a distin\u00e7\u00e3o entre medicamentos acabados \u00e9 importante - NHD","description":"SS-31 e elamipretide s\u00e3o nomes usados \u200b\u200bem torno do mesmo pept\u00eddeo direcionado \u00e0s mitoc\u00f4ndrias, mas Forzinity \u00e9 um medicamento acabado espec\u00edfico aprovado pelo FDA com uma aprova\u00e7\u00e3o\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/pt-br\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","og_locale":"pt_BR","og_type":"article","og_title":"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters","og_description":"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026","og_url":"https:\/\/nhdbio.com\/pt-br\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:05+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"},"wordCount":246,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","articleSection":["Evidence &amp; Quality Guides"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","url":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","name":"SS-31, Elamipretide e Forzinity: Por que a distin\u00e7\u00e3o entre medicamentos acabados \u00e9 importante - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"SS-31 e elamipretide s\u00e3o nomes usados \u200b\u200bem torno do mesmo pept\u00eddeo direcionado \u00e0s mitoc\u00f4ndrias, mas Forzinity \u00e9 um medicamento acabado espec\u00edfico aprovado pelo FDA com uma aprova\u00e7\u00e3o\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mat\u00e9rias-primas pept\u00eddicas e s\u00edntese personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipe T\u00e9cnica NHD","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"A equipe t\u00e9cnica NHD mant\u00e9m documenta\u00e7\u00e3o de cat\u00e1logo de uso em pesquisa e resumos de evid\u00eancias. Os artigos revisados \u200b\u200bvinculam-se a artigos revisados \u200b\u200bpor pares, registros de ensaios e registros regulat\u00f3rios, ret\u00eam resultados nulos e limita\u00e7\u00f5es de estudos e distinguem interven\u00e7\u00f5es publicadas de materiais de cat\u00e1logo. O desenho assistido por AI pode ser usado para estrutura; os links de origem e os limites das evid\u00eancias permanecem vis\u00edveis. Este trabalho n\u00e3o \u00e9 uma revis\u00e3o independente por pares ou aconselhamento m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/pt-br\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/comments?post=465"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/465\/revisions"}],"predecessor-version":[{"id":511,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/465\/revisions\/511"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media\/630"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media?parent=465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/categories?post=465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/tags?post=465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}